The genetic medicine revolution is underway. Just 18 months ago, very few people in the general population had heard of mRNA vaccines; now, hundreds of millions globally have been vaccinated with one.

Every dog has its day, and Monday was Curia’s as the CDMO got its paws on a new drug manufacturing platform. Curia has enlisted enzymatic DNA production outfit Touchlight to furnish its clients with ...

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...

New results have highlighted the advantages of minicircles over plasmids as they avoid unnecessary bacterial backbone sequences due to higher transfection efficiencies and offer benefits especially in ...

Molecular cloning refers to the replication and recombination of DNA molecules. The first cloning experiments were carried out in the 1970s, when restriction endonucleases were discovered. Restriction ...

Are plasmid DNA issues impacting your mRNA program delivery? Many biotech and pharma companies focused on advanced therapy manufacturing are experiencing challenges associated with their pDNA supply, ...

Touchlight scored another $125 million to boost manufacturing as the company looks to become a leading synthetic DNA producer for genetic medicines. The cell and gene therapy space has exploded in the ...

HAMPTON, England--(BUSINESS WIRE)--Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion ...